A randomized, open-label study of the effect of Fuzeon [enfuvirtide] plus a highly active antiretroviral therapy (HAART) compared with HAART alone on viral load suppression and safety in patients currently on antiretroviral therapy.

Trial Profile

A randomized, open-label study of the effect of Fuzeon [enfuvirtide] plus a highly active antiretroviral therapy (HAART) compared with HAART alone on viral load suppression and safety in patients currently on antiretroviral therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2012

At a glance

  • Drugs Antiretrovirals; Enfuvirtide
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms INTENSE
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2008 The actual completion date for the trial is Apr 2008, actual patient number is 47.
    • 16 Apr 2008 Status changed from in progress to completed according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top